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ore Risk Factors
ffecting Heart Failure Outcomes!
ime for Hope or Despair?*
aved Butler, MD, MPH, FACC
ashville, Tennessee; and Boston, Massachusetts
remendous progress has been made over the last two
ecades in the management of patients with heart failure
ue to left ventricular dysfunction. Recent large randomized
eta-blocker trials in these patients have shown a single-
igit annual mortality rate (range 7.2% to 8.8%) and a
eduction in hospitalization rate in excess of 20% (1–3).
espite these improvements, the road ahead is humbling.
ue to the extremely high prevalence, the actual morbidity
nd mortality associated with heart failure remains astro-
omical. It is estimated that currently there are over 5
illion people in U.S. who have heart failure, with an
nnual incidence rate of over 500,000. Heart failure still
ccounts for over 250,000 deaths and over a million hospi-
alizations annually (4). In fact, both the incidence and the
revalence of heart failure continue to increase. This is
ttributable to a combination of the aging of the population
n general and improved outcomes from other acute cardio-
ascular diseases, which in turn provide patients a chance to
ive, albeit with abnormal ventricular function. Another less
ell-studied possibility is that the risk factors for develop-
ent of heart failure may also be increasing in the general
opulation.
See pages 1011 and 1019
Thus, despite the overall decrease in mortality rate with
ewer therapies in recent years, if the current epidemic
ontinues to evolve, the absolute number of deaths due to
eart failure at the population level may actually increase
ather than decrease in the future. Moreover, many recent
eart failure therapies that once showed promise failed to
eplicate the same beneficial results in larger trials (5). In
hort, heart failure burden continues to increase; although
utcomes have improved, they are still unacceptable, and
he benefits with newer therapies seem to be reaching a
lateau.
Given these realities, where do we go from here? One
nswer is to discover new risk factors for heart failure and
xplore novel therapies. Two studies in this issue of the
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiovascular Medicine, Vanderbilt University Medicalp
enter, Nashville, Tennessee, and the Department of Radiology, Massachusetts
eneral Hospital, Harvard Medical School, Boston, Massachusetts.ournal have done exactly this. Doehner et al. (6) have
eported on the importance of insulin resistance as a risk
actor for adverse heart failure outcomes. Although the
elationship between insulin resistance and coronary artery
isease has been researched for some time now, its associ-
tion with survival in heart failure patients is not well
ocumented. Prospectively investigating 105 male patients
ith an ejection fraction of 28  2%, the investigators
ompared outcomes based on patients’ state of insulin
ensitivity. During a mean follow-up period of 44  4
onths, almost half the patients died. For comparative
urposes, patients were divided into those with above and
hose below median insulin sensitivity measured for the
ohort. Patients with lower insulin sensitivity had lower
jection fraction (24  2% vs. 33  3%) and peak exercise
xygen consumption (16.8  1.0 ml/kg/min vs. 19.9  1.0
l/kg/min). Patients with lower insulin sensitivity had
orse survival than did those with above-median values, and
hen adjusted for various differences between the two
roups, higher insulin sensitivity predicted better survival.
In the second study, Meyer et al. (7) assessed the
mportance of impaired endothelium-dependent flow-
ediated vasodilation in patients with heart failure. They
tudied 75 patients with depressed ejection fraction. The
rimary end point for this study was a combined outcome of
ither patient death or conversion to United Network for
rgan Sharing (UNOS) status 1 while awaiting cardiac
ransplantation. Event-free survival rate was higher in pa-
ients with flow-mediated vasodilation above the median
alue compared with those below. Only 19% of patients
bove the median cut-off value, but 63% below it, reached
he combined end point. Flow-mediated vasodilation was
ndependently related to the risk of reaching the combined
nd point.
Although both these results are interesting and have
otential therapeutic implications, they have to be viewed
autiously. In the study by Doehner et al. (6), the overall
ne-year mortality rate was 22%. This is higher than
xpected for a group of patients with an average peak
xercise oxygen consumption of 17.9  0.7 ml/kg/min and
ould suggest sub-optimal management. Indeed, this is the
ase. Only 20% of these patients were on beta-blockers, and
e do not have the information on defibrillator use. It is
nyone’s guess whether this relationship between insulin
esistance and mortality would remain true if all eligible
atients were on standard therapy. What is almost certain is
hat even if there were an adverse link between insulin
esistance and mortality identified in such an idealized
reatment paradigm, it would be of a different (perhaps
esser?) magnitude. Another interesting issue is the emerg-
ng data on differences in beta-blockers with respect to their
ffect on insulin sensitivity, and how that would affect these
esults (8).
In the study by Meyer et al. (7), the event rate is driven
rimarily by the patient’s conversion to UNOS status 1 and
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Editorial Comment September 20, 2005:1027–8ot by mortality. How to account for transplantation and
entricular assist device use in heart failure studies is an
nresolved problem. Conversion to UNOS status 1, which
resumably was primarily related to continuous inotrope
se, is even more subjective. The study by Meyer et al. (7)
ould have been more convincing if there was an adverse
elationship demonstrated with mortality. Another issue is
hether this relationship represents a risk factor or a risk
arker for adverse outcomes. Many correlates of impaired
ow-mediated vasodilation are also associated with worsen-
ng heart failure itself (e.g., oxidative stress and neurohor-
onal activation). However, impaired flow-mediated vaso-
ilation may worsen heart failure progression through
schemia and changes in ventricular afterload, as stated by
he authors. Finally, the “independent” prognostic power of
ny risk factor depends largely on what it is compared
gainst, and in this study we do not have the information on
ome of the standard risk predictors in heart failure.
However, the epidemiologic and therapeutic implications
f these results are enormous. Western society is facing a
rowing obesity, insulin resistance, and metabolic syndrome
hallenge. These studies suggest a possibility of improving
eart failure outcomes by treating insulin resistance. Indeed,
recent study showed significant benefit with insulin
ensitizers in heart failure patients with diabetes (9). If these
esults are replicated, it would not be surprising that such
rugs like thiazolidinediones may become part of the
herapeutic armamentarium for heart failure. A recent
linical trial showed significant survival benefit in heart
ailure patients with carvedilol as compared to metoprolol
artarate (3). Could this be in part related to differences in
nsulin sensitivity profile (8) between these agents? If insulin
esistance is a determinant of heart failure outcomes, the
ifferences between various beta-receptor antagonists will
ecome even more clinically relevant, providing additional
vidence to support the superiority of carvedilol over beta-1
elective adrenergic antagonists. With insulin resistance and
iabetes, the heart uses an excess of free fatty acids and has
educed metabolism of glucose. Thus one may expect drugs
hat optimize myocardial metabolism in patients with insu-
in resistance to potentially improve heart failure outcomes.
ndeed, ranolazine is associated with an improvement in left
entricular function in animal models of heart failure (10).
Similarly, will drugs that improve flow-mediated vasodi-
ation (e.g., statins) improve heart failure outcomes? Studies
uggest improved heart failure outcomes with statins, and a
linical trial is underway (11). Another interesting questionhat arises is whether the impaired flow-mediated vasodila-
ion and insulin resistance are related, and are these two
tudies both leading us in the same direction (12). Finally,
ased on these findings, novel pharmacologic agents may be
eveloped that target these pathophysiologic abnormalities.
In short, both groups of investigators should be congrat-
lated for their interesting findings. However, the hard
ork of proving these hypotheses, replicating the results,
nd, more importantly, translating them into therapeutic
dvances needs to begin soon.
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